All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Cognitive comparison

P21 vs Semax

An educational, source-based comparison of P21 and Semax — how each peptide works, what it's researched for, and what to know before going deeper.

Nootropic · Neuroprotection
P21

Synthetic nootropic peptide researched for synaptic plasticity.

Mechanism

A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.

Research areas
  • Synaptic plasticity and memory
  • Neuroprotection in Alzheimer's models
  • Cognitive recovery after brain injury
Considerations
  • Experimental; limited human data available.
  • Not FDA-approved.
Full P21 profile →
Nootropic · Neuroprotection
Semax

Russian-origin peptide studied for focus and neuroprotection.

Mechanism

A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.

Research areas
  • BDNF/NGF upregulation
  • Ischemic stroke recovery (clinical use in Russia)
  • Attention and cognitive performance
  • Anxiolytic-style effects
Considerations
  • Approved as a medication in Russia; not FDA-approved in the US.
  • Most clinical literature is in Russian.
Full Semax profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

P21
Preliminary

Early-stage research; conclusions are tentative.

1 cited study
Semax
Limited

Two cited studies; independent replication needed.

2 cited studies

Study-by-study comparison

PeptideStudySourceYearSummary
P21P21 promotes synaptic plasticity in aged rodentsNeuroscience Letters2015Enhanced dendritic spine density and BDNF expression in hippocampal tissue.
SemaxSemax in the treatment of ischemic strokeZhurnal Nevrologii i Psikhiatrii2018Reported improved neurological recovery scores in acute ischemic stroke.
SemaxSemax and its analogs in neuroprotectionMolecular Neurobiology2020Review of neurotrophic and antioxidant mechanisms.

Side-effect & safety grid

P21
  • Experimental; limited human data available.
  • Not FDA-approved.
Semax
  • Approved as a medication in Russia; not FDA-approved in the US.
  • Most clinical literature is in Russian.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

P21 vs Semax — Key differences

  • Class: P21 is classified as Nootropic · Neuroprotection, while Semax is Nootropic · Neuroprotection.
  • Primary research focus: P21synaptic plasticity and memory; Semaxbdnf/ngf upregulation.
  • Tag: Cognition · Neuroprotection vs Cognition.

Related comparisons